BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda alone.

A promising treatment for one of the deadliest lung cancers has hit a setback that experts did not see coming.

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR ...

Monash University’s Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a ...

The new targeted therapy is designed to block KRAS, a protein that drives many pancreatic cancers, and its approval underscores the importance of clinical trials in advancing treatment options.

Lauren writes about healthcare AI data interoperability, the science behind public health recommendations, and pharmaceutical advances in the rare disease space. In a rare move, nonprofit organization ...

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how ...

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new two-step method promises to revolutionize targeted cancer drug development by ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

The Centre has told the Supreme Court that trade margins on all anti-cancer drugs will be regulated, with an expert committee ...